...
首页> 外文期刊>BMC Urology >Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival
【24h】

Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival

机译:淋巴上皮瘤样,膀胱尿路上皮癌的变体:无病生存的最佳治疗方式的病例报告和系统评价

获取原文
           

摘要

Background Lymphoepithelioma-like carcinoma (LELC) is a rare high-grade carcinoma that resembles nasopharyngeal lymphoepithelioma and can occur throughout the body. First reported in 1991, bladder LELC has an incidence of about 1% of all bladder carcinomas. Due to its rare occurrence, prognoses and ideal treatment guidelines have not been clearly defined. Methods A PubMed search was performed using two terms, “lymphoepithelioma-like carcinoma” and “bladder.” Review articles, articles in foreign languages, expression studies, and studies not performed in the bladder were excluded. We report a case of LELC of the bladder including treatment and outcome and performed a systematic review of all 36 available English literatures from 1991 to 2016 including the present case to identify factors affecting disease-free survival. Results One hundred forty cases of bladder LELC were analyzed. The mean age of the patients was 70.1?years ranging from 43 to 90?years with 72% males and 28% females. Pure LELC occurs most often at 46% followed by mixed LELC 28% and predominant LELC 26%. EBV testing was negative in all cases tested. Mean follow-up length for all cases was 33.8?months with no evidence of disease in 62.2%, while 11.1% died of disease, 10.4% alive with metastasis, and 8.2% died without disease. 5.0% of cases had recurrence at an average of 31.3?months. Prognosis is significantly favorable for patients presenting with pure or predominant forms of LELC compared to mixed type ( p Conclusion We conclude that the best treatment modality associated with the highest disease-free survival is multi-modal treatment including radical cystectomy.
机译:背景淋巴上皮瘤样癌(LELC)是一种罕见的高级别癌,类似于鼻咽淋巴上皮瘤,可在全身发生。 1991年首次报道,膀胱LELC占所有膀胱癌的约1%。由于其罕见的发生,预后和理想的治疗指南尚未明确定义。方法使用两个术语“淋巴管上皮瘤样癌”和“膀胱”进行PubMed搜索。排除评论文章,外语文章,表达研究和未在膀胱中进行的研究。我们报告了包括治疗和结果在内的膀胱LELC病例,并对包括本例在内的1991年至2016年间所有36篇可用的英语文献进行了系统回顾,以确定影响无病生存的因素。结果分析140例膀胱LELC。患者的平均年龄为70.1岁,从43岁到90岁,男性为72%,女性为28%。单纯性LELC的发生率最高,为46%,其次是混合性LELC,为28%,主要为LELC,为26%。在所有测试的案例中,EBV测试均为阴性。所有病例的平均随访时间为33.8个月,无疾病证据的占62.2%,而疾病死亡的占11.1%,活着转移的占10.4%,无疾病死亡的占8.2%。 5.0%的病例平均复发31.3个月。与混合型相比,LELC纯或优势型患者的预后显着好(p结论我们得出结论,与最高无病生存期相关的最佳治疗方式是包括根治性膀胱切除术在内的多模式治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号